ReviewFrontiers in immunology2026
Pathogenesis and intervention strategies for metabolic dysfunction-associated fatty liver disease from the perspective of the gut-microbiota-liver axis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transcriptomic timeseries links hepatic gene expression to an early and self-limited systemic response to enteric infection.PLoS pathogens · 2026Article
- Relationship between triglyceride-glucose-derived obesity indices and NAFLD in adolescents: A cross-sectional study.Medicine · 2026Article
- Potential mechanisms by which microbiota-accessible carbohydrates regulate hepatic lipid metabolism in MAFLD via the gut-liver axis.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trillions of microorganisms in the human gut are important regulators of health, and the gut and liver have a symbiotic relationship with them. The study found that there is bidirectional communication of substances and signals between the gut and liver, and the gut microbiota is an important medium for mediating bidirectional communication in the gut-liver axis. During metabolic dysfunction-associated fatty liver disease (MAFLD) development, the gut microbiota and its metabolites change to different degrees and affect MAFLD pathogenesis through the gut-liver axis. However, the bidirectional communication mechanism between the gut and liver in MAFLD remains unexplored, and further investigation in this domain is warranted. In this review, we summarize the role of the gut-liver axis in the pathogenesis of MAFLD and explore potential therapeutic strategies targeting intestinal microecology (such as probiotic intervention and phage therapy) to provide a theoretical basis for the precise prevention and treatment of MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.